Probiotics for Digestive Health

Engineered gut bacteria that can consume carbohydrates and synthesize fiber to improve gut health. The bacteria are modified to express a fiber-synthesizing enzyme that uses carbohydrates to produce fiber in the gut. Administering these bacteria can decrease carbohydrate levels and increase fiber levels in the gut. This aims to counteract the negative effects of excessive carbohydrate consumption and insufficient fiber intake on gut microbiome composition and health.

Source

Composition of bacteria that can be used as therapeutic probiotics to treat conditions related to chronic inflammation of the gastrointestinal tract like IBD. The composition includes strains like Akkermansia species, Bacteroides uniformis, Bacteroides xylanisolvens, Clostridium butyricum, Clostridium scindens, Clostridium symbiosum, Eubacterium callanderi, Extibacter species, and Intestinimonas butyriciproducens. These strains have been identified in healthy human gut microbiomes and have properties like producing short-chain fatty acids and indole metabolites that can help restore gut homeostasis and reduce inflammation.

Source

Lactic acid bacteria strain Lactiplantibacillus plantarum KM2 isolated from aged meat that exhibits proteolytic activity, immunity enhancement, and probiotic properties. The strain has potential applications as an ingredient in probiotics, functional foods, and pharmaceuticals.

Source

Lactobacillus strain IMAU80584 that has potential probiotic uses for fermentation of dairy products and inhibiting pathogenic bacteria. It has acid-producing abilities, acid tolerance, and ability to grow over a wide range of temperature and pH conditions. The strain can be used as a fermentation agent for making fermented milk products like soy or cow milk. It can also be used as a supplement to prevent and treat pathogenic bacterial infections.

Source

Preventing and treating intestinal microbiome aberrations in Cesarean section-born infants to improve their health and prevent disorders. The method involves administering a composition containing specific bacterial species to CS-born infants to correct their microbiome. The composition comprises at least one Bacteroides species (e.g., Bacteroides vulgatus) and/or at least one Bifidobacterium species (e.g., Bifidobacterium longum). This can be given soon after birth to mimic the natural maternal transmission of bacteria during vaginal birth.

Source

Probiotic strain Lactobacillus paracasei 207-27 isolated from infant intestines. The strain has high survivability against gastric acid and bile salts, good adhesion to intestinal mucosa, and can activate immune cells to secrete anti-inflammatory cytokines like IL-10. Administering this strain can inhibit inflammation, improve immunity, and alleviate allergies.

Source

Strains of the bacteria Parabacteroides distasonis for use in the treatment and prevention of gastrointestinal diseases, such as inflammatory bowel diseases, and disorders associated with gastrointestinal diseases. The strains can be administered in live or inactivated forms. The strains are selected from specific Parabacteroides distasonis strains that have been deposited.

Source

Solid enterically-coated dosage forms of bacteria or bacterial extracellular vesicles that can be orally administered to modulate immune and physiological effects in the body. The enteric coating allows release in the small intestine where the bacteria can interact with immune and epithelial cells. This targeted delivery to the small intestine enhances the effectiveness compared to non-enterically coated forms. The dosage forms can contain isolated bacterial extracellular vesicles, bacteria, or both.

Source

Soft, chewable gummies or tablets containing kombucha tea powder. The formulation combines bacterial and yeast treated tea powder with a biopolymer like pectin and sugar to make a gummy matrix. The gummies can also contain other ingredients like vitamins, minerals, probiotics, flavorings, and colors.

Source

Reactivating lyophilized probiotics to confer a proper negative zeta-potential on the cell surface of the probiotics. The composition includes amino acids like L-lysine or L-tyrosine that reactivate lyophilized probiotics and improve their functionality by conferring a suitable negative zeta potential on the cell surface of the lyophilized probiotics. This improves intestinal survivability and adhesion by reactivating lyophilized probiotics and conferring a proper negative zeta-potential on them.

Source

A strain of Pediococcus acidilactici bacteria called TAK 589 Coccobest that can be used as a probiotic additive in food and beverages to improve gut health. The strain has antimicrobial and antioxidative properties that help stabilize the gastrointestinal microbiota and prevent infections. It can be used as a probiotic for humans and animals, as well as a starter culture for fermenting plant matter. The strain is resistant to antibiotics and does not suppress beneficial lactobacilli.

Source

Probiotic tablets and powders containing isomaltulose as the excipient. The use of isomaltulose as a replacement for conventional excipients like isomalt in probiotic products that improves viability, stability, and dental health. The tablets and powders are made by mixing probiotic bacteria with isomaltulose and compressing or packaging the mixture.

Source

A strain of Lactobacillus rhamnosus, designated CMU-pb-7, isolated from human feces. The strain exhibits probiotic properties and can be used in various applications such as dietary supplements, functional foods, and pharmaceuticals. The strain has potential to be developed into antioxidant drugs to treat or prevent diseases associated with oxidative stress.

Source

A method for producing encapsulated probiotics with improved stability and viability, as well as a method of treating disease using the encapsulated probiotics. The method involves culturing probiotics in a medium containing alginate and a salt that forms a hydrogel. The acid produced by the probiotics dissociates the cation from the salt, allowing the alginate to spontaneously form a hydrogel entrapping the probiotics. The encapsulated probiotics are then recovered. This simple method provides encapsulated probiotics that have improved freeze-drying viability, heat tolerance, and shelf stability compared to conventional encapsulation techniques.

Source

Strain of the gut bacteria Akkermansia muciniphila, identified as AK32. The strain can be used to develop pharmaceuticals, probiotics, functional foods and supplements for preventing or treating intestinal damage and improving gut health. The strain produces a unique enzyme that may contribute to its beneficial effects.

Source

A defined bacterial cocktail for treating gastrointestinal disorders like Clostridioides difficile infections (CDI) that provides an alternative to fecal microbiota transplantation (FMT). The cocktail is a Live Biotherapeutic Product (LBP) comprising carefully selected, purified, and cultured bacterial strains isolated from healthy donors. These strains can be precisely detected and quantified in recipients using computationally enabled strain tracking. This allows monitoring of engraftment, efficacy, and long-term stability of the donor strains. The LBP provides a defined, effective, and trackable bacterial treatment for gut disorders.

Source

Using Adlercreutzia bacterial strains for treating inflammatory diseases like non-alcoholic fatty liver disease (NAFLD) and inflammatory bowel diseases (IBD). The Adlercreutzia strains, such as Adlercreutzia equolifaciens, exhibit anti-inflammatory effects and can reduce symptoms like weight gain, hyperglycemia, and liver inflammation in disease models.

Source

Use of lactic acid bacteria or fermented products to maintain or improve gastrointestinal health by reducing Helicobacter pylori infection which can cause gastric issues. The lactic acid bacteria strains Lactobacillus paracasei ET-66, Lactobacillus salivarius subsp. salicinius AP-32, and Lactobacillus plantarum LPL28 were found to adhere to gastric cells, inhibit H. pylori growth and urease activity, and agglutinate H. pylori. Administering compositions containing these strains or their fermentation products provides a natural and safe way to improve gastrointestinal health.

Source

Lactic acid bacteria composition containing lactic acid bacteria (Lactobacillus paracasei) and amino acids (lysine, arginine, and glutamate) as active ingredients to protect the bacteria from gastric acid and bile conditions. The amino acids enhance expression of the gadC gene in the bacteria, which helps them survive acidic environments. The composition can be used in probiotics, functional foods, etc.

Source

Novel Lactobacillus reuteri strain that promotes intestinal development and maturation. The strain, called Lactobacillus reuteri DS0384, can be used in products like probiotics, fermented foods, pharmaceuticals, health foods, and animal feed to enhance intestinal health and prevent/treat disorders like inflammatory bowel disease.

Source

Identification, characterization, and use of a specific strain of Bifidobacterium breve (207-1) with probiotic potential. The strain has high tolerance to stomach acid and bile salts, good adhesion to intestinal mucosa, and can stimulate anti-inflammatory cytokine production in immune cells. It can enhance immunity, inhibit inflammation, and alleviate allergic symptoms.

Source

A novel strain of Faecalibacterium prausnitzii bacteria, Faecalibacterium prausnitzii KBL1027, and its potential therapeutic use for treating inflammatory diseases, preventing dysbiosis and improving gut health. The strain exhibits anti-inflammatory activity by inducing IL-10 production, strengthens intestinal tight junctions, and improves intestinal microbial balance.

Source

A Bacillus coagulans strain, BC198, for preventing or ameliorating chemotherapy-induced intestinal lesions and flora imbalances. The Bacillus coagulans BC198, when administered before and during chemotherapy, protects intestinal cells, reduces lesions, maintains intestinal flora balance, and lowers inflammation factors compared to placebo.

Source

A postbiotic extract derived from probiotic microbes for improving gut health and inhibiting biofilm formation. The extraction process involves mixing a protein material (like whey) with probiotic cells, adding a polysaccharide material (like dextrin) to form a precipitate, and extracting the postbiotic compounds from the precipitate. The resulting extract contains bioactive components from the probiotic cell walls. It can be used as a food additive or medical treatment to promote gut health and prevent biofilm growth.

Source

A synergistic combination of probiotic bacterial strains and prebiotic fibers that can be used to optimize and modulate the gut microbiota for improved health. The probiotics are specific strains of Bifidobacterium pseudocatenulatum and Bifidobacterium longum, while the prebiotic is xylooligosaccharide (XOS). Administering these two together in a ratio of 100:1 to 1:100 can promote growth of these beneficial bacteria in the gut.

Source

A nutritional composition containing Bifidobacterium longum subsp. longum and Lacto-N-tetraose (LNT) to improve gut health in infants and young children. The B. longum subspecies is known to be present in high amounts in breastfed infants and has beneficial effects like reducing inflammation and promoting healthy bacteria growth. LNT is a component of breast milk that B. longum subspecies can utilize. The combination of B. longum subspecies with LNT synergistically enhances gut microbiota activity, engraftment, short chain fatty acid production, beneficial bacteria growth and reduces inflammation compared to using either alone.

Source

Biocompatible biomaterial using cellulose and probiotics to prevent and treat infections without antibiotics. The biomaterial entraps live probiotic bacteria within a cellulose matrix, which inhibits pathogenic bacteria growth. The cellulose is produced by aerobic bacteria together with facultative anaerobic probiotic bacteria, followed by anaerobic incubation to promote probiotic proliferation. The probiotics survive and actively hinder pathogens when entrapped in cellulose. The biomaterial can be used in medicine, food coatings, and packaging to prevent infections.

Source

Promoting healthy gut microbiota and preventing gut inflammatory conditions in infants and children by increasing serpin protein production. The method involves growing Bifidobacterium longum subsp longum in a culture medium containing the prebiotic lacto-N-tetraose (LNT) to increase serpin production. Administering B. longum subsp longum and LNT together can also be used to promote healthy gut microbiota and prevent gut inflammation in infants and children. The combination of B. longum and LNT can improve the intestinal environment for bacterial colonization and reduce inflammation risk.

Source

Stabilizing probiotics using surface-reacted calcium carbonate to extend shelf life, which is derived from natural ground calcium carbonate reacted with carbon dioxide and acid. The stabilizer is mixed with a probiotic culture and dried. The stabilized dry probiotic composition can contain at least 106 viable cells per gram even at room temperature. This is much higher than typical probiotic products. The calcium carbonate stabilizer prevents degradation during drying and storage.

Source

Genetically engineered bacteria that secrete anti-inflammatory compounds to treat gastrointestinal inflammatory diseases like IBD.

Source

Method to alleviate lactose intolerance symptoms using a specific probiotic called Bifidobacterium adolescentis strain IVS-1. The probiotic is administered to aid lactose digestion in lactose intolerant individuals. The probiotic strain is selected by in vivo enrichment in the human gut using a prebiotic and has genetic adaptations to outcompete gas producing bacteria for lactose and lactose-like carbohydrates in the gut, reducing gas production and symptoms.

Source

Probiotic fermented fruit and vegetable puree made using a specific Lactobacillus casei bacterial strain to ferment fresh fruits and vegetables. The fermented puree has an improved flavor and nutritional profile compared to prior art products that use essences and lose nutrients during processing. The strain is resistant to gastric acid and bile salts, adheres to intestinal cells, and has antioxidant and antibacterial properties. The fermented puree has a mellow taste, pleasant fragrance, and probiotic benefits.

Source

A Lactobacillus casei strain that produces high levels of short-chain fatty acids when cultured. These fatty acids have beneficial effects on gut health. The strain is isolated and identified from the human body and can be cultured using specific conditions to maximize fatty acid production.

Source

A method to enhance the survival, persistence and probiotic effects of Lactobacillus reuteri strains, particularly for mineral absorption, by pre-conditioning the bacteria with galacto-oligosaccharides during cultivation. The pre-conditioned L. reuteri strain improves mineral solubility, accessibility and absorption in the gastrointestinal tract when ingested.

Source

Composition containing Bifidobacterium longum subsp. infantis to promote gastrointestinal tract development and prevent or treat intestinal diseases. It also improves lung function and prevents/treats lung diseases, and enhances immune function.

Source

Using Lactobacillus sakei CVL-001 strain to prevent or treat inflammatory diseases like bowel conditions. The strain activates NOD2, an inflammation regulator, and effectively reduces body weight loss and improves disease activity in a colitis mouse model.

Source

Using a specific Bifidobacterium longum probiotic strain to improve the fermentability of plant fibers with a high insoluble fraction. The probiotic, Bifidobacterium longum subsp. longum, is particularly effective at fermenting plant fibers like pea and corn bran that have a high insoluble fraction. Co-supplementing these fibers with the probiotic increases short chain fatty acid production compared to fibers alone. This combination could produce health benefits without excess gas. It also showed potential anti-inflammatory effects in the human gastrointestinal tract.

Source

Using a specific Bifidobacterium longum probiotic strain that produces serpin proteins to prevent symptoms of accidental gluten exposure in individuals with Celiac Disease who follow a gluten-free diet. The serpin proteins inhibit gluten digestion and the production of immunogenic/toxic peptides from gluten in the gut. Administering the probiotic strain daily alongside the gluten-free diet can mitigate the effects of hidden gluten and reduce symptoms in CD patients.

Source

Lactiplantibacillus plantarum TCI837 as a potential probiotic strain that can promote iron absorption and improve gut microbiota. It increases the bioavailability of iron to help alleviate iron-deficiency anemia symptoms, such as fatigue, by increasing red blood cell count and heme levels. The strain also enhances intestinal health by promoting beneficial probiotic growth while inhibiting harmful bacteria.

Source

A yogurt containing multiple strains of probiotics, prebiotics, and dietary fibers to improve intestinal health. The yogurt can prevent constipation and gestational diabetes in overweight/obese pregnant women by regulating their intestinal microbiome. The yogurt contains lactic acid bacteria like Lactobacillus and Bifidobacterium strains, along with prebiotic fibers like inulin, fructooligosaccharides, and galactooligosaccharides.

Source

A composition of three specific strains of probiotic bacteria for improving gut health and treating gastrointestinal disorders. The probiotic strains Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 are combined in specific ratios. Administering the composition can boost gastrointestinal barrier function, alleviate barrier dysfunction disorders, and inhibit growth of harmful gut bacteria. The strains can be provided in food or pharmaceutical products.

Source

A composition containing a microencapsulated saffron extract with at least 0.2% safranal along with probiotic bacteria and/or yeast. The composition can be used to improve irritable bowel syndrome (IBS), sleep, immunity, and stress disorders. The specific saffron extract quantity and microencapsulation method allows it to work synergistically with the probiotics to provide enhanced benefits for these conditions.

Source

A method to enable probiotics to colonize the gut long-term. It involves modifying both the probiotics and the intestinal mucosa using bioorthogonal click chemistry. The method uses a precursor to introduce a bioorthogonal functional group onto the intestinal mucosa. This altered mucosa can then selectively bind probiotics that have been modified with a complementary functional group.

Source

Probiotic preparation using a double emulsion structure that improves stability and viability of probiotics compared to conventional capsule encapsulation. The preparation method involves forming an internal water phase containing probiotics, mixing with a lipid phase to form a water-in-oil primary emulsion, and then adding an external water phase to create a stable W1/O/W2 double emulsion containing the probiotics. The double emulsion protects the probiotics from oxygen, temperature, pH, digestive enzymes, and bile salts during storage and digestion, leading to better survival and functionality.

Source

Better tasting and more healthful kefir made using specific strains of bacteria and yeast selected from kefir grains. The strains include Lactobacillus kefiranofaciens and Lactobacillus kefiri bacteria, plus Pichia fermentans, Saccharomyces cerevisiae, Kazachstania unispora, and Kluyveromyces marxianus yeasts. These strains can be combined and added to milk to make kefir. The resulting kefir has been shown to reduce cholesterol and liver triglycerides in animal models.

Source

A Lactobacillus helveticus strain that is effective in preventing and treating inflammatory bowel disease. The strain, designated as KCTC 14110BP, showed therapeutic effects on an inflammatory bowel disease-induced mouse model. When orally administered to mice with the disease, the strain increased body weight, improved survival rates, increased colon length, and showed uniform intestinal tissue compared to control groups.

Source

Combining immunosuppressant drugs like cyclosporin A or TNF inhibitors like adalimumab with specific Lactobacillus strains like Lactobacillus buchneri, paracasei, and zeae, can effectively treat inflammatory bowel disease and reduce pro-inflammatory cytokine expression.

Source

A food composition to promote gut health that includes Lactobacillus mucosae, a strain of lactic acid bacteria with an ability to increase short-chain fatty acids and diversity of gut bacteria. The composition can be used in foods, drinks, and supplements. It can also be used as a probiotic to improve gut health by administering the bacteria to a subject. The composition is identified using a model of human gut microbiota that has specific bacterial species representative of Japanese individuals.

Source

Using short-chain fatty acids (SCFAs) to inhibit bacterial conjugation and horizontal gene transfer in the gut to control the spread of antibiotic resistance genes and virulence factors. Administering SCFAs or SCFA-producing probiotics to the gut inhibits bacterial conjugation, preventing transfer of plasmids containing antibiotic resistance genes and virulence factors between bacteria.

Source

A bacterial composition for treating dysbiosis-related diseases. The composition includes two purified bacterial populations. The first population has specific bacterial strains while the second population has strains with functional features like anti-inflammatory activity, epithelial restoration, engraftment capability, bile acid production, etc.

Source